anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a liver function-protecting or improving agent, a liver function protecting or improving food, beverage or feed, an additive for a food, beverage or feed having the liver function-protecting or improving activity, and a method for protecting or improving the liver function of an animal. SOLUTION: This liver function-protecting or improving agent is characterized by containing a plant body or plant extract of Artemisia apiacea Hance or Apium graveolens L. var. rapaceum Mill. DC. as an active ingredient, and the food, beverage or feed obtained by adding the plant body or plant extract of the Artemisia apiacea Hance or Apium graveolens L. var. rapaceum Mill. DC. is also provided.
INTRODUCTION: Almost two-fifth of the children in India is stunted and among various factors, poverty differential in child undernutrition is the largest. Using the latest population-based survey of National Family Health Survey, 2015-16 and 2019-21 this paper examined the poverty induced inequality in child stunting across the sub-populations of India.
METHODS: A sample of 213,136 children aged between 0-5 years from NFHS fourth round and 98,222 children in the same age group from the NFHS fifth round constitute the study sample. The wealth index is used as the proxy of household's economic wellbeing and height-for-age (HAZ) z-score of a child is used to identify the stunting status of the child. Box plots are drawn to understand the distributional characteristics of the HAZ score for both the study sample. We calculate the Erreygers corrected concentration index and decomposed the concentration indices using Gonzalo-Almorox and Urbanos-Garrido method.
RESULTS: During 2015-16, more than half of the children from the poorest wealth quintile were stunted (52%), compared to 22% among the children from richest wealth quintile. In 2015-16, stunting was as high as 65% among the children of mothers with low stature (height less than 145 cm) and from the poorest wealth quintile whereas, the prevalence was observed 56% from the same sub-population during 2019-21. Among various factors, the concentration index of stunting was observed highest among the children of 36-47 months (-0.28) followed by children of age 48-59 months (-0.27) and among the fully immunized children (-0.25). Similar to NFHS-4, NFHS-5 also shows a predominantly higher socio-economic inequality among 24+ months children and among the fully immunised children. Factors like child age, birth order and sanitation showed positive elasticity. Decomposition analysis of NFHS-4 data shows that due to uneven distribution of wealth, mother's education as a determinant of child stunting solely explained 33% of the overall inequality followed by improved access to sanitation (24%), mother's height (8%) and place of residence (5%). Similar to NFHS-4, NFHS-5 data also shows that mother's education, sanitation, mother's height and place of residence predominantly contributes to the overall wealth inequality in child stunting.
CONCLUSIONS: In India, poverty differential in child undernutrition is acute among the different sub-population of children. And the concentration of stunted children is higher among the different sub-population with higher wealth poverty. Mother's education, improved sanitation and mother's height explained larger variation in the overall inequalities in child nutrition across India.
The present invention relates to the method for treating obesity and overweight and gastro-oesophageal reflux disease (GERD). According to the invention the method for treating obesity and overweight and gastro-oesophageal reflux disease lies in the fact that the stem and regenerative cells extracted from adipose tissue (ADRC - Adipose Derived Regenerative Cells) are injected into the submucosa tissue or muscle near the gastric cardia and fundus. The isolated ADRC cells are given via endoscopy or surgical procedures, open or laparoscopic. The isolated ADRC cells are enriched with fat graft in the amount of at least 5 ml and not more than 25 ml. The method is complementary to other bariatric procedures reducing the size of the stomach - such as adjustable gastric band, gastric sleeve partial resection,or filling the stomach - as intragastric implants, or affecting the motility or satiety induction by electrical stimulation (neurostimulators). It is preferred when the method is applied while other surgical procedures to obese or overwieght patients. In the treatment of gastro-oesophageal reflux disease the stem and regenerative cells isolated from its own adipose tissue (ADRC - Adipose Derived Regenerative Cells) are injected into the submucosa or muscle tissue around gastric cardia.
Herpes zoster virus infectious facial paralysis is caused by the reactivation and replication of varicella-zoster virus, which leads to herpetic inflammatory lesions, resulting in peripheral facial paralysis associated with herpes rash in the auricle and external ear, and vestibular cochlear dysfunction. It is also known as Ramsey-Hunter syndrome (Hunt syndrome). Facial paralysis caused by herpes zoster is difficult to cure due to its easy loss of treatment and mistreatment. Cause a greater burden on the patient's body and mind. However, the treatment of Western medicine has lagged behind and there are many adverse reactions, which cannot be completely cured, and new alternatives are urgently needed. This article briefly reviews the advantages and disadvantages of modern medical treatment of Hunt syndrome. This paper expounds the unique ideas of traditional Chinese medicine in the treatment of Hunt syndrome from the perspectives of antiviral, antibacterial, improving blood circulation, protecting cardiovascular, cerebrovascular, and nerve. This article discusses the superiority of traditional Chinese medicine in the treatment of Hunt syndrome from 2 aspects of Chinese medicine therapy and acupuncture therapy, and points out the feasibility of combined treatment of acupuncture and traditional Chinese medicine. So as to provide a new treatment for Hunt syndrome.
Post-hepatectomy liver failure (PHLF) is a potentially life-threatening complication following liver resection. Hepatocellular carcinoma (HCC) often occurs in patients with chronic liver disease, which increases the risk of PHLF. This study aimed to investigate the ability of the combination of liver function and fibrosis markers (ALBI score and FIB-4 index) to predict PHLF in patients with HCC. Patients who underwent hepatectomy for HCC between August 2012 and September 2022 were considered for inclusion. Multivariable logistic regression analysis was used to identify factors associated with PHLF, and ALBI score and FIB-4 index were combined based on their regression coefficients. The performance of the combined ALBI-FIB4 score in predicting PHLF and postoperative mortality was compared with Child-Pugh score, MELD score, ALBI score, and FIB-4 index. A total of 215 patients were enrolled in this study. PHLF occurred in 35 patients (16.3%). The incidence of severe PHLF (grade B and grade C PHLF) was 9.3%. Postoperative 90-d mortality was 2.8%. ALBI score, FIB-4 index, prothrombin time, and extent of liver resection were identified as independent factors for predicting PHLF. The AUC of the ALBI-FIB4 score in predicting PHLF was 0.783(95%CI: 0.694-0.872), higher than other models. The ALBI-FIB4 score could divide patients into two risk groups based on a cut-off value of - 1.82. High-risk patients had a high incidence of PHLF of 39.1%, while PHLF just occurred in 6.6% of low-risk patients. Similarly, the AUCs of the ALBI-FIB4 score in predicting severe PHLF and postoperative 90-d mortality were also higher than other models. Preoperative ALBI-FIB4 score showed good performance in predicting PHLF and postoperative mortality in patients undergoing hepatectomy for HCC, superior to the currently commonly used liver function and fibrosis scoring systems.
Unraveling the intricacies of soybean cyst nematode (Heterodera glycines) race 4 resistance and susceptibility in soybean breeding lines-11-452 (highly resistant) and Dongsheng1 (DS1, highly susceptible)-was the focal point of this study. Employing cutting-edge N6-methyladenosine (m6A) and RNA sequencing techniques, we delved into the impact of m6A modification on gene expression and plant defense responses. Through the evaluation of nematode development in both resistant and susceptible roots, a pivotal time point (3 days postinoculation) for m6A methylation sequencing was identified. Our sequencing data exhibited robust statistics, successful soybean genome mapping, and prevalent m6A peak distributions, primarily in the 3' untranslated region and stop codon regions. Analysis of differential methylation peaks and differentially expressed genes revealed distinctive patterns between resistant and susceptible genotypes. In the highly resistant line (11-452), key resistance and defense-associated genes displayed increased expression coupled with inhibited methylation, encompassing crucial players such as R genes, receptor kinases, and transcription factors. Conversely, the highly susceptible DS1 line exhibited heightened expression correlated with decreased methylation in genes linked to susceptibility pathways, including Mildew Locus O-like proteins and regulatory elements affecting defense mechanisms. Genome-wide assessments, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses, and differential methylation peak/differentially expressed gene overlap emphasized the intricate interplay of m6A modifications, alternative splicing, microRNA, and gene regulation in plant defense. Protein-protein interaction networks illuminated defense-pivotal genes, delineating divergent mechanisms in resistant and susceptible responses. This study sheds light on the dynamic correlation between methylation, splicing, and gene expression, providing profound insights into plant responses to nematode infection.
<P>PROBLEM TO BE SOLVED: To provide the use of a molded contact lens in combination with a pharmaceutical composition suitable for delivering to the eye.  <P>SOLUTION: The molded contact lens is preferably marketed and is not specially designed for orthokeratology. A factor (e.g. hyaluronidase) in the pharmaceutical composition forms the cornea of the eye to correct ametropia of the eye. The contact lens and the pharmaceutical composition cause change of the radius of curvature of the front surface of cornea to correct ametropia of the eye. One of advantages of the technique of the invention is to control the treatment for individual patients having visual necessity to satisfy the necessity to near visual acuity and distance visual acuity of the patient. A kit is also provided. The kit includes the molded contact lens, the pharmaceutical composition suitable for a system for delivering to the eye and an instruction.  <P>COPYRIGHT: (C)2011,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a sustained release enteric coating preparation having excellent appearance, strength and safety. SOLUTION: An enteric substance having an average particle diameter of <=10μm and pH or 5-8 (e.g. hydroxypropyl methyl cellulose acetate succinate) is applied to the surface of a formed solid material containing a drug-active substance while spraying a wax in melted state. The spraying of wax melt is carried out by a conventional rotary granulator while fluidizihng the formed solid material and the addition of the fine powder of the enteric substance is performed by manual operation or with a powder-supplying and scattering apparatus. There is no particular restriction on the mixing weight ratio of the meltable substance and the enteric substance. It has high rate of dissolution of the drug component in the 2nd liquid of the Japanese Pharmacopoeia.  The sustained release effect can be imparted in addition to the enteric property without applying an additional coating layer simply by decreasing the weight of the enteric substance relative to the meltable substance.
The investigators will use a randomized, double-blind, sham-controlled design of bilateral theta burst stimulation (BL-TBS) to dorsolateral prefrontal cortex (DLPFC) administered 5 days per week for 6 weeks (30 sessions). The investigators will recruit n=80, 16-35 year old participants with autism that do not have co-occurring intellectual disability (ID). In the current study, the target population will be individuals with autism, without ID who have co-occurring clinically significant depression. Pre/post treatment MRI will be used to study mechanisms of treatment response. The investigators will build on their previous pilot rTMS study in autism with two key innovations. First, the investigators will use theta burst stimulation (TBS) for depression as opposed to conventional rTMS. TBS is a newer form of rTMS shown to be non-inferior to conventional rTMS for depression with a similar safety profile. Tolerance of intermittent TBS (iTBS, delivered at 100% RMT to right DLPFC in ten 9-17 year-olds with ASD) has already been shown in autism in a prior open-label study. Importantly, TBS can be delivered in a fraction of the time needed for conventional rTMS. This shorter administration time may be critical for participant retention as sensory sensitivity is a major feature of autism. A shorter administration also has important practical implications for future clinical access. The investigators will use BL-TBS based on: preliminary data of improved antidepressant efficacy with a bilateral (over unilateral) TBS approach that combines left excitatory with right inhibitory DLPFC stimulation, as well as findings that bilateral (over unilateral) rTMS may improve suicidal ideation in MDD.
Refining method for separating biologically active substances and/or substance groups from a mixture of several prenylated polyphenols, comprises (i) providing a solution of the mixture, (ii) applying the solution on a solid phase, (iii) eluting at least one biologically active substance from the solid phase by a gradual succession of different solvents, and (iv) collecting respective eluates comprising the biologically active substance and/or substance groups, obtained in the step (iii). A solvent mixture of a solvent and cyclodextrin derivative is used for at least one step of step (iii). An independent claim is also included for an active agent recovered by the above refining method, comprising a specific proportion of regioisomers of the active substance. ACTIVITY : Neuroprotective; Cytostatic. No biological data given. MECHANISM OF ACTION : None given.
Process for obtaining water soluble extracts of low mol. wt. and contg. diaminopimelic acid from E. coli cells comprises subjecting the de-lipidised bacterial residue of E. coli cells to a weak extn., and isolating the water soluble extracts by physicochemical methods. The weak extraction can be carried out by homogenisation in an aq. medium opt. in the presence of a non ionic detergent. The extracts obtd. are novel and are used as immunological adjuvants to increase antibody prod., they do not have arthrogenic activity. In adult humans doses are 10-50 mg/day.
The present invention relates to an improved composition for preserving active extracts obtained from the Ulomoides Dermestoides beetle, the process for obtaining the same and uses thereof, in particular for use in the pharmaceutical and homeopathic industry. The present invention aims to provide active extracts of the Ulomoides Dermestoides beetle in an improved composition without the need to consume live beetles. Also, aims to provide a micro-dose as a form of treatment for treating and/or preventing diseases and/or conditions related to diabetes and arthritis. Said composition characterizes by comprising the following components in wt.%: i) liquid soy lecithin in an amount of up 22.75% to 24.99%; ii) liquid xylitol in an amount of up 22.75% to 24.99%; iii) glycerin gel in an amount of up 22.75% to 24.99%; iv) gelled agar in an amount of up 22.75% to 24.99%; v) milk kefir kefirán in an amount of up 0.01% to 3%; vi) water kefir kefirán in an amount of up 0.01% to 3%; and vii) lichen from Iceland in an amount of up 0.01% to 3%. Further, it comprises active extracts of Ulomoides Dermestoides beetle, in a ratio of up 1:3 to 3:1, preferably 1: 1, and a hydro-alcoholic solution in a ratio of up 1:20 to 20:1, preferably 1:17 to 17:1. Additionally, it involves two parts of 96° cane alcohol and one part of water selected from distilled water, deionized water, spring water and carbonated water. Finally, the improved composition may optionally be lyophilized.
This study is designed as a prospective, multi-center randomized double-masked placebo-controlled trial of caspofungin versus placebo for prevention of invasive candidiasis in high-risk adults in the critical care setting. The objective of this study is to evaluate the efficacy of caspofungin as prophylaxis for invasive candidiasis in high-risk ICU subjects by comparing the risk of invasive candidiasis in subjects receiving caspofungin with the risk in those receiving placebo. The secondary objectives are to evaluate the rate of invasive candidiasis in subjects meeting the clinical prediction rule; to prospectively assess the effect of colonization as a risk factor for the development of invasive candidiasis; to evaluate the safety of caspofungin as prophylaxis for invasive candidiasis by summarizing the proportion of subjects who discontinue study therapy because of a drug-related adverse event and the proportion of subjects with one or more drug-related adverse event(s); and to evaluate all-cause mortality. The planned sample size will be 1200 subjects, 1/3 in the control arm and 2/3 in the active treatment arm based on a power of at least 0.8 needed to detect a 50% reduction in incidence from base rate of 11% to 5.5%. High-risk icu subjects greater than or equal to 18 years of age meeting all eligibility criteria with at least 5 days of anticipated ICU stay will be randomized to receive either caspofungin 50 mg/day (70 mg/day for subjects on rifampin) or placebo (normal saline) daily. Caspofungin or placebo will be given intravenously as a single daily dose infused over approximately one hour. Subjects will receive study drug or placebo for the duration on their icu stay, up to a maximum of 28 days.
Arm A: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
Endometriosis is the condition involving the presence of glands or stroma of the endometrial lining outside the uterus cavity. Its characteristics include unpleasant pain in the pelvic region, impaired fertility, pain during or after sex, and heavy bleeding during periods. Endometriosis occurs as a result of genetic, angiogenic, immunological, and inflammatory factors. In endometriosis, adhesions may be formed due to local inflammation. It can also occur as the blood-filled implants start bleeding in their surroundings. As a result of this bleeding healing occurs which causes scar formation. Pharmacologically, NSAIDS are used for instant pain relief. The most common surgical approach is laparoscopy. Physiotherapy in its various forms can be an excellent complement to the gynecological treatment of endometriosis. as previous studies also reported the effect of pelvic massage, pelvic manipulation, kinesiotherapy, and hydrotherapy. According to researcher knowledge, there is limited evidence on wurn technique and mercier therapy and how these techniques improve dyspareunia, dysmenorrhea, and quality of life in women with endometriosis. This study aims to see the comparative effects of wurn technique and mercier therapy on dyspareunia, dysmenorrhea, and quality of life in women with endometriosis.
Cellular sensitivity to ferroptosis is primarily regulated by mechanisms mediating lipid hydroperoxide detoxification. We show that inositol-requiring enzyme 1 (IRE1α), an endoplasmic reticulum (ER) resident protein critical for the unfolded protein response (UPR), also determines cellular sensitivity to ferroptosis. Cancer and normal cells depleted of IRE1α gain resistance to ferroptosis, while enhanced IRE1α expression promotes sensitivity to ferroptosis. Mechanistically, IRE1α's endoribonuclease activity cleaves and down-regulates the mRNA of key glutathione biosynthesis regulators glutamate-cysteine ligase catalytic subunit (GCLC) and solute carrier family 7 member 11 (SLC7A11). This activity of IRE1α is independent of its role in regulating the UPR and is evolutionarily conserved. Genetic deficiency and pharmacological inhibition of IRE1α have similar effects in inhibiting ferroptosis and reducing renal ischemia-reperfusion injury in mice. Our findings reveal a previously unidentified role of IRE1α to regulate ferroptosis and suggests inhibition of IRE1α as a promising therapeutic strategy to mitigate ferroptosis-associated pathological conditions.
The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Three vaccinia virus CD8 +  T cell epitopes restricted by the most common human M.C. class I allele, HLA-A0201, were identified. Each of these epitopes is highly conserved in vaccinia and variola viruses. In addition, the induction of the T cell responses following primary vaccination with two of these epitopes is demonstrated by the kinetics of epitope specific CD8 +  T cells in 3 HLA-A0201 individuals. Two vaccinia virus CD8 +  T cell epitopes restricted by another common human M.C. class I allele, HLA-B7, also were identified. Both epitopes are highly conserved in vaccinia and variola viruses. This information will be useful for the design and analysis of the immunogenicity of experimental vaccinia vaccines, and for basic studies of human T cell memory.
Patients undergo a comprehensive physical, psychological, social, and spiritual palliative care assessment. Patients also receive a workbook that covers physical and psychological well-being and social and spiritual well-being, delivered over 2 educational sessions.